INCY - Incyte Corp Stock Analysis
Incyte Corp (INCY) is a publicly traded company listed on the NASD. It operates in the Biotechnology industry, part of the broader Healthcare sector. The company has a market capitalization of 19.72B, generates annual revenue of 4.81B, and reports net income of 1.19B. As of the latest data, the stock is trading at 100.46 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock appears reasonably valued, potentially indicating balanced risk and return. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company has very low leverage, which may indicate conservative financial management or underutilization of debt. This stock does not currently pay a dividend. The stock has average market volatility, aligning with general market movement.
Analyst recommendation stands at No Data (None), indicating current market sentiment. Institutional ownership is reported at 103.74%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 37.17%, trading within a 52-week range of 53.56 - 109.28.
INCY - Incyte Corp
100.46
Analyst Consensus
No Data None
INCY – Analyst Rating Summary
No analyst data available
No Data
| Index: | S&P 500 | P/E: | 16.85 | EPS (ttm): | 5.96 | Insider Own: | 1.09% | Shs Outstand: | 196.13M | Perf Week: | -4.91% |
| Market Cap: | 19.72B | Forward P/E: | 12.76 | EPS next Y: | 7.87 | Insider Trans: | -11.41% | Shs Float: | 194.20M | Perf Month: | -2.39% |
| Income(ttm): | 1.19B | PEG: | 0.16 | EPS next Q: | 1.95 | Inst Own: | 103.74% | Short Float: | 4.89% | Perf Quarter: | 15.95% |
| Revenue(ttm): | 4.81B | P/S: | 4.10 | EPS this Y: | 525.80% | Inst Trans: | 1.65% | Short Ratio: | 4.47 | Perf Half Y: | 49.41% |
| Book/sh: | 23.71 | P/B: | 4.24 | EPS next Y: | 16.87% | ROA: | 20.96% | Short Interest: | 9.50M | Perf Year: | 37.17% |
| Cash/sh: | 14.92 | P/C: | 6.73 | EPS next 5Y: | 105.25% | ROE: | 30.39% | 52W Range: | 53.56 - 109.28 | Perf YTD: | 45.45% |
| Dividend Est.: | - | P/FCF: | 16.48 | EPS past 3/5Y: | -66.90% -40.36% | ROIC: | 25.39% | 52W High: | 109.28 -8.07% | Beta: | 0.82 |
| Dividend TTM: | - | Quick Ratio: | 3.13 | Sales past 3/5Y: | 12.41% 14.46% | Gross Margin: | 91.55% | 52W Low: | 53.56 87.57% | Perf 5Y: | 20.67% |
| Dividend Ex-Date: | - | Current Ratio: | 3.20 | EPS Y/Y TTM: | 3563.21% | Oper. Margin: | 26.10% | RSI (14): | 49.05 | Volatility: | 2.58% 2.90% |
| Employees: | 2617 | Debt/Eq: | 0.01 | Sales Y/Y TTM: | 18.09% | Profit Margin: | 24.69% | Recom: | 2.43 | Target Price: | 96.80 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.01 | EPS Q/Q: | 287.38% | Payout: | 0.00% | Rel Volume: | 0.93 | Prev Close: | 101.50 |
| Sales Surprise: | 8.91% | EPS Surprise: | 40.71% | Sales Q/Q: | 20.05% | Earnings: | Oct 28 BMO | Avg Volume: | 2.12M | Price: | 100.46 |
| SMA20: | -3.57% | SMA50: | 5.70% | SMA200: | 31.45% | Overbought: 3.64% | Volume: | 1,982,373 | Change: | -1.02% | |
Graham Classic formula value: 1172.05
(P/E=8 * 1g) Min value: 606.1
(current P/E * 2g) Max value: 1216.74
Average value: 998.3
About Incyte Corp
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.